Literature DB >> 18634146

Toll-like receptor 4 and CD14 polymorphisms in ankylosing spondylitis: evidence of a weak association in Finns.

Jennifer J Pointon1, Kay Chapman, David Harvey, Anne-Marie Sims, Linda Bradbury, Kari Laiho, Markku Kauppi, Kalevi Kaarela, Jaakko Tuomilehto, Matthew A Brown, B Paul Wordsworth.   

Abstract

OBJECTIVE: To investigate the association of CD14 and Toll-like receptor (TLR4) with ankylosing spondylitis (AS).
METHODS: A promoter variant in CD14 and 2 coding polymorphisms in TLR4 were investigated in UK and Finnish families with AS and in a UK case-control study. A metaanalysis of published TLR4 and CD14 studies was performed.
RESULTS: In the Finnish study the CD14-260bp T variant showed an association (p = 0.006), and the common 2-marker TLR4 haplotype showed a weak association (global p = 0.03), with AS. No associations were seen in the UK based studies or in the metaanalyses.
CONCLUSION: CD14 and TLR4 showed an association with AS in the Finns only.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18634146

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

Review 1.  Recent studies on the genetic basis of ankylosing spondylitis.

Authors:  John D Reveille
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

2.  Genetic and Functional Associations with Decreased Anti-inflammatory Tumor Necrosis Factor Alpha Induced Protein 3 in Macrophages from Subjects with Axial Spondyloarthritis.

Authors:  Yiping Liu; Zhan Ye; Xiang Li; Jennifer L Anderson; Mike Khan; Douglas DaSilva; Marissa Baron; Deborah Wilson; Vera Bocoun; Lynn C Ivacic; Steven J Schrodi; Judith A Smith
Journal:  Front Immunol       Date:  2017-07-24       Impact factor: 7.561

3.  TLR-4 and VEGF polymorphisms in chronic periaortitis.

Authors:  Fabiola Atzeni; Luigi Boiardi; Augusto Vaglio; Davide Nicoli; Enrico Farnetti; Alessandra Palmisano; Nicolò Pipitone; Davide Martorana; Gabriella Moroni; Selena Longhi; Francesco Bonatti; Carlo Buzio; Carlo Salvarani
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.